Gene Biotherapeutics, Inc.

CRXM · OTC
Analyze with AI
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Assets
Cash & Equivalents$386$0$82$49
Short-Term Investments$0$0$0$0
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$25$32$19$25
Total Curr. Assets$411$33$101$74
Property Plant & Equip (Net)$149$3$61$124
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$7$0$0$12
Total NC Assets$156$3$61$136
Other Assets$0$0$0$0
Total Assets$567$35$162$210
Liabilities
Payables$746$967$1,858$1,870
Short-Term Debt$1,153$999$1,066$1,231
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$3,129$2,797$2,867$2,254
Total Curr. Liab.$5,027$4,763$5,791$5,356
LT Debt$108$122$0$0
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$10
Total NC Liab.$108$122$0$10
Other Liabilities$0$0$0$0
Cap. Leases$150$0$0$0
Total Liabilities$5,135$4,885$5,791$5,366
Equity
Pref Stock$0$0$0$0
Common Stock$4$1$1$1
Retained Earnings-$119,430-$118,912-$119,779-$119,344
AOCI$0$600$600$600
Other Equity$115,551$114,021$114,021$113,941
Total Equity-$3,875-$4,290-$5,157-$4,802
Supplemental Information
Minority Interest-$693-$560-$472-$354
Total Liab. & Tot. Equity$567$35$162$210
Net Debt$874$1,121$984$1,182